文献速递类风湿关节炎

巴瑞替尼对比安慰剂或阿达木单抗治疗类风湿关节炎的3期研究患者报告结局:RA-BEAM研究次要分析

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
PubMed 文献 · Ann Rheum Dis · 2017-08-10

该3期双盲研究纳入甲氨蝶呤应答不佳的活动性类风湿关节炎患者,随机分为安慰剂组(n=488)、巴瑞替尼4mg每日一次组(n=487)或阿达木单抗40mg每两周一次组(n=330),均联用背景甲氨蝶呤。第12周时,巴瑞替尼在HAQ-DI、PtGA、疼痛、FACIT-F、SF-36躯体成分评分、EQ-5D指数评分及WPAI-RA日常活动方面较安慰剂和阿达木单抗均显示统计学显著改善(p≤0.05),且改善维持至第52周。

要点

  • 巴瑞替尼较安慰剂和阿达木单抗显著改善HAQ-DI、PtGA、疼痛、疲劳及生活质量等患者报告结局。
  • 患者日记显示的晨僵持续时间与严重程度、最差疲劳和最差关节痛在第12周显著改善。
  • 上述患者报告结局的改善维持至研究终点第52周。

核心结论

  • 巴瑞替尼在多数患者报告结局方面较安慰剂和阿达木单抗提供显著更大改善,包括躯体功能、晨僵、疼痛、疲劳和生活质量,且改善维持至第52周。

研究设计与样本

  • 双盲3期研究,患者按3:3:2随机分配至安慰剂组(n=488)、巴瑞替尼4mg每日一次组(n=487)或阿达木单抗40mg每两周一次组(n=330),均联用背景甲氨蝶呤,主要终点为第12周。

主要发现

  • 第12周时,巴瑞替尼在HAQ-DI、PtGA、疼痛、FACIT-F、SF-36躯体成分评分、EQ-5D指数评分和WPAI-RA日常活动方面较安慰剂和阿达木单抗均显示统计学显著改善(p≤0.05)。
  • 第12周时,巴瑞替尼在患者日记测量的晨僵持续时间和严重程度、最差疲劳及最差关节痛方面较安慰剂和阿达木单抗均显示统计学显著改善(p≤0.05)。
  • 截至第52周,所评估指标的改善得以维持。

关键数值与推荐

  • 治疗比较采用逻辑回归分析分类变量或协方差分析连续变量。
  • 统计学显著性阈值设定为p≤0.05。

临床怎么用

  • 对于甲氨蝶呤应答不佳的活动性类风湿关节炎患者,巴瑞替尼在躯体功能、晨僵、疼痛、疲劳和生活质量等患者报告结局方面可能优于安慰剂和阿达木单抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA), and measures collected in electronic patient daily diaries: duration and severity of morning joint stiffness (MJS), Worst Ttiredness and Worst Joint Pain. The primary study endpoint was at week 12. Treatment comparisons were assessed with logistic regression for categorical measures or analysis of covariance for continuous variables. RESULTS: Compared with placebo and adalimumab, baricitinib showed statistically significant improvements (p≤0.05) in HAQ-DI, PtGA, pain, FACIT-F, SF-36 physical component score, EQ-5D index scores and WPAI-RA daily activity at week 12. Improvements were maintained for measures assessed to week 52. Statistically significant improvement in patient diary measures (MJS duration and severity), worst tiredness and worst joint pain were observed for baricitinib versus placebo and adalimumab at week 12 (p≤0.05). CONCLUSIONS: Baricitinib provided significantly greater improvement in most PROs compared with placebo and adalimumab, including physical function MJS, pain, fatigue and quality of life. Improvement was maintained to the end of the study (week 52). TRIAL REGISTRATION: NCT01710358.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017. PMID: 28798049. doi:10.1136/annrheumdis-2017-211259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。